Stock Analysis·← Pickers

DVA

DaVita Inc.

DaVita Inc. (DVA) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 68.5, with 3/3 trend checks passing.

Price
$231.61
-0.80 (-0.34%)
Day range
$225.17–$232.21
52wk $101.00–$239.64
Volume
462.9K
Avg
Trend score
3/3
Uptrend
RSI (14)
68.5
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DVA with MA50 and MA200

235.7202.8169.8136.8103.907/3110/2401/2204/1707/15
DVA2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$205.75+12.57% vs price
MA200
$150.21+54.19% vs price
RSI (14)
68.5Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

DVA valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

DVA analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for DVA

DaVita Inc. (DVA) is still trading in a constructive trend overall. The latest available price is $231.61, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 12.6% and above the 200-day moving average by 54.2%.

Momentum and stretch context

DVA currently has an RSI reading of 68.5, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

For traders reviewing DVA next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About DaVita Inc.

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Javier J. Rodriguez
Employees
78,000
Market cap
$15.05B
Beta
0.88
52-week range
$101.00 – $239.64
Dividend
No
Exchange
NYSE
Country
US
IPO date
31 Oct 1995
ISIN
US23918K1088
CUSIP
23918K108
Website
davita.com
Company profile data from Financial Modeling Prep. DVA listed on NYSE.
Share dilution

DVA shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
67.4M
Since Jun 2019
-59.5%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. DVA28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DVA

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.